"And then perhaps a second on the iptacopan breakthrough designation in PNH and C3G. Alexion has been historically quite clear, they don't expect the oral complement assets to challenge C5 agents as the mainstay therapy, rather only in refractory patients or those with breakthrough hemolysis. So would you disagree with that view? Was the breakthrough designation also covering naive patients or just the refractory subgroups, for example? And just a bit of thoughts in terms of the midterm outlook in that space?"